Durability of clinical benefit with transcranial magnetic stimulation (TMS) in the treatment of pharmacoresistant major depression: Assessment of relapse during a 6-month, multisite, open-label study

Brain Stimulation

Volumn 3, Issue 4, 2010, Pages 187-199

  Janicak, Philip G ^a   Nahas, Ziad ^b   Lisanby, Sarah H ^c   Solvason, H Brent ^d   Sampson, Shirlene M ^e   McDonald, William M ^f   Marangell, Lauren B ^g   Rosenquist, Peter ^h   McCall, W Vaughn ^h   Kimball, James ^h   O'Reardon, John P ⁱ   Loo, Colleen ^j   Husain, Mustafa H ^k   Krystal, Andrew ^l   Gilmer, William ^m   Dowd, Sheila M ^a   Demitrack, Mark A ⁿ   Schatzberg, Alan F ^d  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^d STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^e MAYO CLINIC   (United States)

^f EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g BAYLOR COLLEGE OF MEDICINE   (United States)

^h WAKE FOREST UNIVERSITY HEALTH SCIENCES   (United States)

ⁱ HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^j UNIVERSITY OF NEW SOUTH WALES   (Australia)

^k UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^l DUKE UNIVERSITY MEDICAL CENTER   (United States)

^m NORTHWESTERN UNIVERSITY   (United States)

ⁿ Neuronetics   (United States)

more..

Author keywords

Antidepressant; Clinical trial; Maintenance of effect; Major depression; TMS; Treatment resistance

Indexed keywords

ANTIDEPRESSANT AGENT;

CONTROLLED STUDY; DEVICES; DOUBLE BLIND PROCEDURE; FOLLOW UP; HAMILTON SCALE; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MONOTHERAPY; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MULTICENTER STUDY; OPEN STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL; REVIEW; SURVIVAL RATE; TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT OUTCOME; TREATMENT RESISTANT DEPRESSION; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; FEMALE; METHODOLOGY; MIDDLE AGED; PROSPECTIVE STUDY; RECURRENT DISEASE;

ADULT; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; PROSPECTIVE STUDIES; RECURRENCE; TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT OUTCOME;

EID: 79952277151     PISSN: 1935861X     EISSN: 18764754     Source Type: Journal    
DOI: 10.1016/j.brs.2010.07.003     Document Type: Review

References (20)

1. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006;163:1905-1917. (Pubitemid 44807782)
2. O'Reardon JP, Solvason B, Janicak PG, et al. Efficacy and safety of repetitive transcranial magnetic stimulation (rTMS) in the acute treatment of major depression: results of a multicenter randomized ontrolled trial. Biol Psychiatry 2007;62:1208-1216. (Pubitemid 350060890)
3. Janicak PG, O'Reardon JP, Sampson SM, et al. Transcranial magnetic stimulation in the treatment of major depressive disorder: a comprehensive summary of safety experience from acute exposure, extended exposure, and during reintroduction treatment. J Clin Psychiatry 2008; 69:222-232. (Pubitemid 351469265)
4. Avery DH, Isenberg KE, Sampson SM, et al. TMS in the acute treatment of major depression: clinical response in an open-label extension trial. J Clin Psychiatry 2008;69:441-451. (Pubitemid 351549398)
5. Lisanby SH, Husain MM, Rosenquist PB, et al. Daily left prefrontal repetitive transcranial magnetic stimulation in the acute treatment of major depression: clinical predictors of outcome in a multisite, randomized controlled clinical trial. Neuropsychopharmacology 2009;34:522-534.
6. DemitrackMA, ThaseME. Clinical significance of transcranial magnetic stimulation (TMS) in the treatment of pharmacoresistant depression: synthesis of recent data. Psychopharmacol Bull 2009;42:5-38.
7. George MS, Lisanby SH, Avery D, et al. Daily left prefrontal transcranial magnetic stimulation therapy for major depressive disorder. Arch Gen Psychiatry 2010;67:507-516.
8. Dannon PN, Dolberg OT, Schreiber S, Grunhaus L. Three and six-month outcome following courses of either ECT or rTMS in a population of severely depressed individualsdpreliminary report. Biol Psychiatry 2002;51:687-690. (Pubitemid 34310507)
9. O'Reardon JP, Blumner KH, Peshek AD, Pradilla RR, Pimiento PC. Long-term maintenance therapy for major depressive disorder with rTMS. J Clin Psychiatry 2005;66:1524-1528. (Pubitemid 43068690)
10. Fitzgerald PB, Benitez J, de Castella AR, Brown TL, Daskalakis ZJ, Kulkarni J. Naturalistic study of the use of transcranial magnetic stimulation in the treatment of depressive relapse. Aust N Z J Psychiatry 2006;40:764-768. (Pubitemid 44145219)
11. Demirtas-Tatlidede A, Mechanic-Hamilton D, Press DZ, et al. An open-label, prospective study of repetitive transcranial magnetic stimulation (rTMS) in the long-term treatment of refractory depression: reproducibility and duration of the antidepressant effect in medication-free patients. J Clin Psychiatry 2008;69:930-934. (Pubitemid 351944945)
12. Cohen RB, Boggio PS, Fregni F. Risk factors for relapse after remision with repetitive transcranial magnetic stimulation for the treatment of depression. Depress Anxiety 2009;26:682-688.
13. Ventura J, Liberman RP, Green MF, Shaner A, Mintz J. Training and quality assurance with the structured clinical interview for DSM-IV (SCID-I/P). Psychiatry Res 1998;79:163-167.
14. Sackeim HA. The definition and meaning of treatment-resistant depression. J Clin Psychiatry 2001b;62(suppl 16):10-17.
15. Williams N, Simpson AN, Simpson K, Nahas Z. Relapse rates with long-term antidepressant drug therapy: a meta-analysis. Hum Psychopharmacol Clin Exp 2009;24:401-408.
16. Sackeim HA, Haskett RF, Mulsant BH, et al. Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: a randomized controlled trial. JAMA 2001;285:1299-1307. (Pubitemid 32216144)
17. Prudic J, Olfson M, Marcus SC, Fuller RB, Sackeim HA. Effectiveness of electroconvulsive therapy in community settings. Biol Psychiatry 2004;55:301-302.
18. Kellner CH, Knapp RG, Petrides G, et al. Continuation electroconvulsive therapy vs pharmacotherapy for relapse prevention in major depression: a multisite study from the Consortium for Research In Electroconvulsive Therapy (CORE). Arch Gen Psychiatry 2006;63: 1337-1344. (Pubitemid 44878518)
19. Tew JD, Mulsant BH, Haskett RF, Joan P, Begley AE, Sackeim HA. Relapse during continuation pharmacotherapy after acute response to ECT: a comparison of usual care versus protocolized treatment. Ann Clin Psychiatry 2007;19:1-4. (Pubitemid 46439716)
20. Rusjan PM, Barr MS, Farzan F, et al. Optimal transcranial magnetic stimulation coil placement for targeting the dorsolateral prefrontal cortex using novel magnetic resonance image-guided neuronavigation [published online ahead of print February 16, 2010]. Hum Brain Mapp 2010.